Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market February 21, 2025, Shanghai – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic […]
chime biologics and mabgeek celebrate ppq success Not available.
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]
Sorry, this entry is only available in 中文. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
Sorry, this entry is only available in 中文. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, […]
Chime Biologics Bridges Innovation and Collaboration at Europe-China Biotech Business Forum 2024 November 4, Stockholm, Sweden – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, bridged Europe-Asia Biotech innovation and collaboration at the Europe-China Biotech Business Forum 2024, a BIO-Europe side event. Bringing together senior pharmaceutical leaders to explore cross-border […]
Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing October 28, 2024, Shanghai, China – Chime Biologics, a leading global CDMO that enables its partners’success in biologics, today announced a strategic collaboration with MedPacto, a South Korean clinically staged company listed on KOSDAQ (235980). MedPacto, known for […]
